SCHEMBL4291899

SCHEMBL4291899

CCN(CC)C(=O)C1(C)CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.38
USP2 O75604 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
EPHX1 P07099 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
MMP2 P08253 1/20 0.34
MMP13 P45452 1/20 0.34
MMP14 P50281 1/20 0.34
ADAM17 P78536 1/20 0.34
CTSK P43235 1/20 0.34
NR1H2 P55055 1/20 0.33
USP30 Q70CQ3 1/20 0.33
ACACB O00763 2/20 0.33
CYP11B2 P19099 1/20 0.33
CKS1B P61024 1/20 0.33
SKP1 P63208 1/20 0.33
SKP2 Q13309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4295250 0.84 EPHX1 (0.41) HPGDEPHX1MEN1KMT2AMAPT
SCHEMBL26316172 0.82 HPGD (0.38) HPGDUSP2SMN1; SMN2EPHX1MEN1
SCHEMBL2279068 0.80 HPGD (0.43) HPGDUSP2SMN1; SMN2EPHX1MEN1
SCHEMBL20482260 0.80 HPGD (0.43) HPGDUSP2SMN1; SMN2EPHX1MEN1
SCHEMBL17407192 0.80 HPGD (0.43) HPGDUSP2SMN1; SMN2EPHX1MEN1
SCHEMBL6943029 0.80 HPGD (0.43) HPGDUSP2SMN1; SMN2EPHX1MEN1
SCHEMBL30453434 0.80 HPGD (0.39) HPGDUSP2SMN1; SMN2EPHX1MEN1
SCHEMBL30453762 0.80 HPGD (0.39) HPGDUSP2SMN1; SMN2EPHX1MEN1
SCHEMBL2891521 0.80 HPGD (0.39) HPGDUSP2SMN1; SMN2EPHX1MEN1
SCHEMBL2228033 0.79 HPGD (0.42) HPGDUSP2SMN1; SMN2EPHX1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281097-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 US disclosed
US-20090281097-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 US disclosed
US-20090281097-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 US disclosed
EP-2009011-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-12-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281097-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TNNC1, CPT1B, TNNI3 HPGD 595/4885USP2 2796/4885SMN1; SMN2 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.